drugset / Trial / NCT05679895
Safety and Efficacy of OC-1 Therapy in Patients With R/R T-ALL/LL
Phase 1
Recruiting
20 enrolled
OneChain Immunotherapeutics
Astrum CRO, S.L. · collabBioClever 2005 S.L. · collabHospital Clinic of Barcelona · collabHospital Sant Joan de Deu · collab
NaSingle-groupOpen-labelTreatment
Summary
First in humans, exploratory, open-label, single-arm, multicentre, non-competitive, dose escalation study to assess the safety and efficacy of CD1a-CAR T therapy in patients with relapsed/refractory (R/R) T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LL)
Timeline
- Start
- 2023-01-31
- Primary completion
- 2027-12
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD1a-CAR T | Cell therapy | — | Intravenous |